GC-MS-Based Endometabolome Analysis Differentiates Prostate Cancer from Normal Prostate Cells

Prostate cancer (PCa) is an important health problem worldwide. Diagnosis and management of PCa is very complex because the detection of serum prostate specific antigen (PSA) has several drawbacks. Metabolomics brings promise for cancer biomarker discovery and for better understanding PCa biochemistry. In this study, a gas chromatography–mass spectrometry (GC-MS) based metabolomic profiling of PCa cell lines was performed. The cell lines include 22RV1 and LNCaP from PCa with androgen receptor (AR) expression, DU145 and PC3 (which lack AR expression), and one normal prostate cell line (PNT2). Regarding the metastatic potential, PC3 is from an adenocarcinoma grade IV with high metastatic potential, DU145 has a moderate metastatic potential, and LNCaP has a low metastatic potential. Using multivariate analysis, alterations in levels of several intracellular metabolites were detected, disclosing the capability of the endometabolome to discriminate all PCa cell lines from the normal prostate cell line. Discriminant metabolites included amino acids, fatty acids, steroids, and sugars. Six stood out for the separation of all the studied PCa cell lines from the normal prostate cell line: ethanolamine, lactic acid, β-Alanine, L-valine, L-leucine, and L-tyrosine.

[1]  Xin Lu,et al.  Discovery and validation of potential urinary biomarkers for bladder cancer diagnosis using a pseudotargeted GC-MS metabolomics method , 2017, Oncotarget.

[2]  Maria de Lourdes Bastos,et al.  Biomarker Discovery in Human Prostate Cancer: an Update in Metabolomics Studies , 2016, Translational oncology.

[3]  C. Barbas,et al.  From sample treatment to biomarker discovery: A tutorial for untargeted metabolomics based on GC-(EI)-Q-MS. , 2015, Analytica chimica acta.

[4]  P. Ditonno,et al.  Metabolomic profiling for the identification of novel diagnostic markers in prostate cancer , 2015, Expert review of molecular diagnostics.

[5]  Roman Kaliszan,et al.  Urine metabolic fingerprinting using LC-MS and GC-MS reveals metabolite changes in prostate cancer: A pilot study. , 2015, Journal of pharmaceutical and biomedical analysis.

[6]  M. Gleave,et al.  Targeting ASCT2‐mediated glutamine uptake blocks prostate cancer growth and tumour development , 2015, The Journal of pathology.

[7]  Ashish Gupta,et al.  Metabolomics-derived prostate cancer biomarkers: fact or fiction? , 2015, Journal of proteome research.

[8]  A. Halama Metabolomics in cell culture--a strategy to study crucial metabolic pathways in cancer development and the response to treatment. , 2014, Archives of biochemistry and biophysics.

[9]  F. Baltazar,et al.  Lactate Transporters in the Context of Prostate Cancer Metabolism: What Do We Know? , 2014, International journal of molecular sciences.

[10]  Alessandro Larcher,et al.  Clinical Use of [-2]proPSA (p2PSA) and Its Derivatives (%p2PSA and Prostate Health Index) for the Detection of Prostate Cancer: A Review of the Literature , 2014, Korean journal of urology.

[11]  Alexander G. Gray,et al.  Feasibility of detecting prostate cancer by ultraperformance liquid chromatography-mass spectrometry serum metabolomics. , 2014, Journal of proteome research.

[12]  M. Koutsilieris,et al.  Novel Tools for Prostate Cancer Prognosis, Diagnosis, and Follow-Up , 2014, BioMed research international.

[13]  Leo L. Cheng,et al.  High‐resolution magic angle spinning 1H MRS in prostate cancer , 2014, NMR in biomedicine.

[14]  G. Kristiansen,et al.  Tissue metabolite profiling identifies differentiating and prognostic biomarkers for prostate carcinoma , 2013, International journal of cancer.

[15]  Yair Lotan,et al.  Metabolomic signatures of aggressive prostate cancer , 2013, The Prostate.

[16]  Rawi Ramautar,et al.  Human metabolomics: strategies to understand biology. , 2013, Current opinion in chemical biology.

[17]  John Kurhanewicz,et al.  Metabolic Reprogramming and Validation of Hyperpolarized 13C Lactate as a Prostate Cancer Biomarker Using a Human Prostate Tissue Slice Culture Bioreactor , 2013, The Prostate.

[18]  V. Adam,et al.  Sarcosine as a Potential Prostate Cancer Biomarker—A Review , 2013, International journal of molecular sciences.

[19]  C. Cooper,et al.  The Present and Future of Prostate Cancer Urine Biomarkers , 2013, International journal of molecular sciences.

[20]  Anastasia K Yocum,et al.  The role of sarcosine metabolism in prostate cancer progression. , 2013, Neoplasia.

[21]  D. Wishart,et al.  Translational biomarker discovery in clinical metabolomics: an introductory tutorial , 2012, Metabolomics.

[22]  David S. Wishart,et al.  HMDB 3.0—The Human Metabolome Database in 2013 , 2012, Nucleic Acids Res..

[23]  Charles Pound,et al.  Identification of Plasma Lipid Biomarkers for Prostate Cancer by Lipidomics and Bioinformatics , 2012, PloS one.

[24]  N. Teixeira,et al.  A gas chromatography-mass spectrometry multi-target method for the simultaneous analysis of three classes of metabolites in marine organisms. , 2012, Talanta.

[25]  S. Sereika,et al.  Effect size estimation: methods and examples. , 2012, International journal of nursing studies.

[26]  Edward D. Karoly,et al.  Prospective Study of Changes in the Metabolomic Profiles of Men during Their First Three Months of Androgen Deprivation Therapy for Prostate Cancer , 2012, Clinical Cancer Research.

[27]  Takashi Ishikawa,et al.  Plasma Free Amino Acid Profiling of Five Types of Cancer Patients and Its Application for Early Detection , 2011, PloS one.

[28]  Bruce J Trock,et al.  Application of metabolomics to prostate cancer. , 2011, Urologic oncology.

[29]  Giuseppe Gallone,et al.  Bio::Homology::InterologWalk - A Perl module to build putative protein-protein interaction networks through interolog mapping , 2011, BMC Bioinformatics.

[30]  A. Shojaie,et al.  Metabolomic Profiling Reveals a Role for Androgen in Activating Amino Acid Metabolism and Methylation in Prostate Cancer Cells , 2011, PloS one.

[31]  H. Keun,et al.  Metabolic signatures of malignant progression in prostate epithelial cells. , 2011, The international journal of biochemistry & cell biology.

[32]  Tao-Tao Liu,et al.  GC/MS-based metabolomic approach to validate the role of urinary sarcosine and target biomarkers for human prostate cancer by microwave-assisted derivatization , 2011, Analytical and bioanalytical chemistry.

[33]  Kurt Miller,et al.  Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression. , 2011, The Journal of urology.

[34]  Pär Stattin,et al.  Metabolomic Characterization of Human Prostate Cancer Bone Metastases Reveals Increased Levels of Cholesterol , 2010, PloS one.

[35]  M. Čuperlović-Culf,et al.  Cell culture metabolomics: applications and future directions. , 2010, Drug discovery today.

[36]  G. Kristiansen,et al.  Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. , 2010, European urology.

[37]  David S. Wishart,et al.  MSEA: a web-based tool to identify biologically meaningful patterns in quantitative metabolomic data , 2010, Nucleic Acids Res..

[38]  J. Céraline,et al.  Identification of novel truncated androgen receptor (AR) mutants including unreported pre‐mRNA splicing variants in the 22Rv1 hormone‐refractory prostate cancer (PCa) cell line , 2010, Human mutation.

[39]  D. Kufe,et al.  Mucins in cancer: function, prognosis and therapy , 2009, Nature Reviews Cancer.

[40]  John T. Wei,et al.  Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression , 2009, Nature.

[41]  E. Riboli,et al.  Fatty acid composition of plasma phospholipids and risk of prostate cancer in a case-control analysis nested within the European Prospective Investigation into Cancer and Nutrition. , 2008, The American journal of clinical nutrition.

[42]  David S. Wishart,et al.  HMDB: a knowledgebase for the human metabolome , 2008, Nucleic Acids Res..

[43]  P. Carroll,et al.  Quantification of choline‐ and ethanolamine‐containing metabolites in human prostate tissues using 1H HR‐MAS total correlation spectroscopy , 2008, Magnetic resonance in medicine.

[44]  D. Ponde,et al.  Comparison of radiolabeled choline and ethanolamine as probe for cancer detection , 2008, Cancer biology & therapy.

[45]  M. Tisdale,et al.  Signaling pathways initiated by beta-hydroxy-beta-methylbutyrate to attenuate the depression of protein synthesis in skeletal muscle in response to cachectic stimuli. , 2007, American journal of physiology. Endocrinology and metabolism.

[46]  Ying Zhang,et al.  HMDB: the Human Metabolome Database , 2007, Nucleic Acids Res..

[47]  S. Shariat,et al.  Variation in prostate specific antigen results from 2 different assay platforms: clinical impact on 2304 patients undergoing prostate cancer screening. , 2004, The Journal of urology.

[48]  U. Kim,et al.  In vitro and in vivo (SCID mice) effects of phytosterols on the growth and dissemination of human prostate cancer PC-3 cells , 2001, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[49]  M. Aickin,et al.  Adjusting for multiple testing when reporting research results: the Bonferroni vs Holm methods. , 1996, American journal of public health.

[50]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[51]  Aihua Zhang,et al.  Cell metabolomics. , 2013, Omics : a journal of integrative biology.

[52]  Daniel B. Vigneron,et al.  Validation of Hyperpolarized 13 C Lactate as a Prostate Cancer Biomarker Using a Human Prostate Tissue Slice Culture Bioreactor , 2012 .

[53]  R. Franklin,et al.  Prostatic fluid electrolyte composition for the screening of prostate cancer: a potential solution to a major problem , 2009, Prostate Cancer and Prostatic Diseases.

[54]  Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. , 2008, Annals of internal medicine.

[55]  R. Franklin,et al.  Concepts of citrate production and secretion by prostate 1. Metabolic relationships , 1991, The Prostate.